open access

Vol 48, No 2 (2017)
Prace poglądowe / Reviews
Published online: 2017-04-01
Submitted: 2017-04-24
Get Citation

Haemate P − use in prophylaxis and treatment of von Willebrand disease and immune tolerance induction in haemophilia A complicated by an inhibitor

Andrzej Mital
DOI: 10.1016/j.achaem.2017.05.002
·
Acta Haematol Pol 2017;48(2):125-129.

open access

Vol 48, No 2 (2017)
Prace poglądowe / Reviews
Published online: 2017-04-01
Submitted: 2017-04-24

Abstract

Haemate P is a plasma-derived concentrate used in the treatment of von Willebrand disease and haemophilia A. In comparison with other concentrates, this product is characterised by a high content of high-molecular-weight multimers. The ratio of von Willebrand factor (vWF:RCo) to factor VIII (FVIII) is 2.4:1. Haemate P is used with a high efficacy and safety when desmopressin (DDAVP) is ineffective or contraindicated, in all forms of von Willebrand disease (vWD), in the treatment of bleeding, in preparation for surgery and in prophylaxis in some patients, especially those with type 3 of the disease. The favourable vWF:RCo/FVIII ratio prevents accumulation of FVIII and related thromboembolic complications. Haemate P has been considered a gold standard in the treatment of von Willebrand disease for many years. This concentrate is used also in haemophilia A replacement therapy. One of the complications of haemophilia A treatment is the development of anti-FVIII antibodies called an inhibitor. The objective of the treatment of those patients is the elimination of the inhibitor, possibly through inducing immune tolerance (IT). The efficacy of Haemate P in immune tolerance induction both in the first and consecutive lines of treatment has been demonstrated by many reports. Replacement of highly-purified and recombinant FVIII concentrates in the case of failure to induce IT to concentrates with a high vWF:RCo content may be a beneficial treatment option in another attempt of inducing IT.

Abstract

Haemate P is a plasma-derived concentrate used in the treatment of von Willebrand disease and haemophilia A. In comparison with other concentrates, this product is characterised by a high content of high-molecular-weight multimers. The ratio of von Willebrand factor (vWF:RCo) to factor VIII (FVIII) is 2.4:1. Haemate P is used with a high efficacy and safety when desmopressin (DDAVP) is ineffective or contraindicated, in all forms of von Willebrand disease (vWD), in the treatment of bleeding, in preparation for surgery and in prophylaxis in some patients, especially those with type 3 of the disease. The favourable vWF:RCo/FVIII ratio prevents accumulation of FVIII and related thromboembolic complications. Haemate P has been considered a gold standard in the treatment of von Willebrand disease for many years. This concentrate is used also in haemophilia A replacement therapy. One of the complications of haemophilia A treatment is the development of anti-FVIII antibodies called an inhibitor. The objective of the treatment of those patients is the elimination of the inhibitor, possibly through inducing immune tolerance (IT). The efficacy of Haemate P in immune tolerance induction both in the first and consecutive lines of treatment has been demonstrated by many reports. Replacement of highly-purified and recombinant FVIII concentrates in the case of failure to induce IT to concentrates with a high vWF:RCo content may be a beneficial treatment option in another attempt of inducing IT.

Get Citation

Keywords

Haemate P; von Willebrand disease; Haemophilia A; Immune tolerance induction

About this article
Title

Haemate P − use in prophylaxis and treatment of von Willebrand disease and immune tolerance induction in haemophilia A complicated by an inhibitor

Journal

Acta Haematologica Polonica

Issue

Vol 48, No 2 (2017)

Pages

125-129

Published online

2017-04-01

DOI

10.1016/j.achaem.2017.05.002

Bibliographic record

Acta Haematol Pol 2017;48(2):125-129.

Keywords

Haemate P
von Willebrand disease
Haemophilia A
Immune tolerance induction

Authors

Andrzej Mital

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl